DALLAS, TX--(Marketwire - September 29, 2009) -
Highlighted Links |
|
|
BioTech Medics, Inc. (PINKSHEETS: BMCS) announced today that they have entered into a wholesaler Distribution Agreement for BioTech’s patented and exclusive SHBAN™ Antimicrobial Hand Sanitizer Products with a Dubai distributor.
The initial income and fees to BioTech for 2009 for the Dubai Distributorship is $58,800 (US) and projected $2,000,000 (US) in sales for 2010.
SHBAN is manufactured at an FDA registered plant. It is a bio-degradable product superior to most anti-bacterial hand sanitizers because 1) SHBAN is longer lasting, SHBAN does NOT contain alcohol gel which has poisoned over 22,000 children in the USA after application; 2) SHBAN is non-toxic when used as directed on humans; 3) SHBAN is non-staining; 4) SHBAN is non-flammable; and 5) SHBAN contains no ammonia, nor bleach, nor Benzalkonium Chloride (BOC), nor Triclosan®, nor thymus vulgaris (which is a potent carcinogen for rodents) nor fragrance, or other lotion ingredients. Most hand sanitizer products cannot make all of these claims.
SHBAN is protected under US Letters of Patent #5,514,808, #5,574,050, #5,679,711 and #5,585,391 and a patent pending for the US and international patent. SHBAN is a trademark of BioTech Medics, Inc. BioTech is seeking and negotiating USA and foreign distributorships at this time and will be announcing more foreign distributorships soon.
SHBAN™ in previous in vitro and in vivo testing has been evaluated for its antimicrobial properties against Staph. Aureus, Staph. Epidermidis, EC. Faecalis, E. Coli and Ps. Aeruginosa. Prior research and clinical studies have been conducted at the University of TX Medical Branch, Galveston, TX; Microbiology & Biochemical Assay Laboratories - Houston, Texas; Pathology Associates, Pasadena, Texas; Texas A & M University - College of Veterinary Medicine, College Station, Texas; Baylor College of Dentistry, Dallas, TX; Allergan, Irvine, CA; Culleen Eye Institute, Baylor College of Medicine, Houston, Texas.
BioTech has recently commenced independent clinical testing of SHBAN™ Hand Sanitizer Solution to determine if it reduces (or kills) the H1N1 (Swine) Influenza A virus.
Interested parties desiring a SHBAN Distributorship should contact BioTech immediately.
Safe Harbor: Forward-Looking Statements
This release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the “Act”). The statements above have not been evaluated by the FDA. SHBAN is not intended to diagnose, treat or cure any disease.
Contact:
Tom Wood
Sr. V.P. Sales
Phone 972-849-3782